Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain

  title={Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain},
  author={Michael H. Baumann and Robert D. Clark and Allison G Budzynski and John S. Partilla and Bruce E. Blough and Richard B. Rothman},
  journal={Annals of the New York Academy of Sciences},
Abstract: 3,4‐Methylenedioxymethamphetamine (MDMA) is a popular illicit drug that evokes transporter‐mediated release of serotonin (5‐HT) and dopamine (DA) from nerve cells. Recently, drug users have ingested combinations of the piperazine analogs, 1‐benzylpiperazine (BZP) and 1‐(m‐trifluoromethylphenyl)piperazine (TFMPP), in an attempt to mimic the subjective effects of MDMA. In the present study, we compared neurochemical effects of MDMA, BZP, and TFMPP in rat brain. The ability of MDMA, BZP… 

Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates

Results indicate that behaviorally relevant doses of MDMA do not induce behavioral stimulant or dopamine transporter-mediated effects in nonhuman primates.

Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past

2 Pharmacology of novel

Compared in vitro release assays at transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT) in rat brain synaptosomes indicate that subtle differences in the chemical structure of transporter ligands can have profound effects on biological activity.

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes

All psychoactive tryptamines are 5-HT2A agonists, but5-HT transporter (SERT) activity may contribute significantly to the pharmacology of certain compounds, and in vitro transporter data confirm structure-activity trends for releasers and uptake inhibitors whereby releasers tend to be structurally smaller compounds.

Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter

The data strongly suggest that amphetamine-type agents deplete vesicular neurotransmitter via a carrier-mediated exchange mechanism rather than via a weak base effect, although this conclusion needs to be confirmed via direct measurement of vesicle pH.

Benzylpiperazine: "A messy drug".




Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions

In vivo microdialysis data are supportive of a state‐dependent, stimulatory role of 5‐HT in the regulation of dopamine release, and are consistent with the view that MDMA increases the extracellular concentration of 4,4‐methylenedioxymethamphetamine by facilitating carrier‐mediated 5‐ HT release, which can be enhanced greatly under conditions in which5‐HT synthesis is stimulated.

The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)

Evidence for the occurrence of MDMA-induced neurotoxic damage in human users remains equivocal, although some biochemical and functional data suggest that damage may occur in the brains of heavy users.

Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies

The results indicate that the overall psychological effects of MDMA largely depend on carrier‐mediated 5‐HT release, while the more stimulant‐like euphoric mood effects of ecstasy appear to relate, at least in part, to dopamine D2 receptor stimulation.

Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

In vitro methods determined the neurochemical mechanism of action of amphetamine, 3,4‐methylenedioxymethamphetamine (MDMA), (+)‐methamphetamine, ephedrine, phentermine, and aminorex, and demonstrated that the most potent effect of these stimulants is to release NE.

Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors.

  • J. NashJ. Brodkin
  • Biology, Chemistry
    The Journal of pharmacology and experimental therapeutics
  • 1991
It is suggestive that MDMA increases the concentration of DA in the striatum, in part, via a carrier-mediated mechanism which is largely independent of its effects on 5-HT release.